Disc Medicine is planning to launch a trial by year's end to test DISC-3405, its treatment candidate for iron overload, in ...

Invisible Disabilities Week may have passed by unnoticed, but many of us live it every day, writes columnist Mary Shaniqua.

Wilson writes that withdrawing has been for him a way to feel safe, but frustrated his ability to connect to others.

Testing for PlGF levels can predict the risk of early-onset preeclampsia during pregnancy in people with sickle cell disease, ...

Tocilizumab was effectively used off-label in four young adults with sickle cell disease (SCD) to treat hyperhemolysis ...

In honor of her 39th birthday, columnist Oluwatosin Adesoye reflects on the lessons she's learned from living with sickle ...

Columnist Mary Shaniqua offers up ideas for managing sickle cell disease to get the most out of busy end-of-year events.

The European Medicines Agency (EMA) has confirmed the continuing suspension of marketing authorization for Pfizer’s sickle cell disease (SCD) treatment Oxbryta (voxelotor) — withdrawn from the market ...

Fewer Black men with SCD are biological parents compared with similarly aged Black men in the overall U.S. population, data ...